)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Captor Therapeutics
Captor Therapeutics (CTX) investor relations material
Captor Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary30 Apr, 2026
Executive summary
Focused on targeted protein degradation (TPD) drug discovery, with a pipeline in oncology and autoimmune diseases, leveraging the proprietary Optigrade platform and aiming for global partnerships and commercialization through licensing and collaborations.
2025 marked by significant clinical progress, including the launch of a Phase 1 trial for viadrudomide (CT-01), preclinical advances for vratitoclax (CT-03), and a new collaboration with a US pharma for NEK7 degraders.
Raised PLN 65.6 million in March 2026 via a private placement, ensuring funding through Q3 2027.
Financial highlights
Revenue from research and development services fell to PLN 4,660 thousand in 2025 from PLN 15,825 thousand in 2024, mainly due to the end of the Ono Pharmaceutical collaboration.
Grant revenue increased to PLN 7,088 thousand (2024: PLN 5,842 thousand).
Operating loss widened to PLN 43,561 thousand (2024: PLN 38,967 thousand); net loss was PLN 41,997 thousand (2024: PLN 38,426 thousand).
Cash and cash equivalents at year-end: PLN 10,719 thousand (2024: PLN 39,257 thousand); financial assets (bonds, funds): PLN 21,391 thousand.
Equity decreased to PLN 23,481 thousand (2024: PLN 64,474 thousand) due to the net loss.
Outlook and guidance
Management expects continued operating losses until partnering agreements are signed.
Financial resources secured to operate until Q3 2027; further partnering and licensing deals are being pursued.
Ongoing and planned clinical trials for lead assets (viadrudomide, vratitoclax) and advanced partnering discussions for NEK7 degraders.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Captor Therapeutics
- CT-01 clinical trial advances, R&D revenue surges, and net loss narrows with strong cash reserves.CTX
Q2 202411 Mar 2026 - Advancing four novel drug projects, with strong grant support and key clinical milestones ahead.CTXQ4 202411 Mar 2026
- Net loss narrowed as R&D revenue rose and clinical trial progress advanced.CTXQ3 202411 Mar 2026
- Lower R&D revenue and a net loss in Q1 2025, with key post-period events impacting outlook.CTXQ1 202511 Mar 2026
- First-in-class degraders for cancer and autoimmune diseases show strong clinical promise.CTXCorporate presentation11 Mar 2026
- Net loss widened on lower R&D revenue, but new grants and collaborations extend funding into 2026.CTXQ3 202511 Mar 2026
- Net loss widened on lower R&D revenue and higher costs, with funding secured through mid-2026.CTXQ2 202511 Mar 2026
Next Captor Therapeutics earnings date
Q1 202627 May, 2026
Captor Therapeutics
Next Captor Therapeutics earnings date
Q1 202627 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage